N. Roche (Paris, France), L. Vanfleteren (Haelen, Netherlands)
Late Breaking Abstract - A randomized clinical study to assess the impact of budesonide/formoterol (BUD/FM) pMDI medication reminders on adherence in COPD patients
G. Criner (Philadelphia, United States of America), T. Cole (Rockville, United States of America), K. Hahn (Boston, United States of America), K. Kastango (Boston, United States of America), J. Eudicone (Wilmington, United States of America), I. Gilbert (Wilmington, United States of America)
|     |
Evaluation of safety, tolerability, pharmacokinetics, and food effect of Danirixin oral tablets in Japanese elderly healthy subjects
Y. Matsuzawa (Tokyo, Japan), H. Ogura (Tokyo, Japan), T. Nagakubo (Tokyo, Japan), A. Wakamatsu (Tokyo, Japan), C. Ambery (Middlesex, United Kingdom), B. Miller (Philadelphia, United States of America), Y. Numachi (Tokyo, Japan)
| |
Population health impact of Indacaterol/Glycopyrronium over 4 years in chronic obstructive pulmonary disease
F. Gutzwiller (Basel, Switzerland), K. Kostikas (Basel, Switzerland), E. Gruen (Basel, Switzerland), M. Sekharan (Hyderabad, India)
| |
Risk of exacerbation and pneumonia with single inhaler triple versus dual therapy in IMPACT
M. Dransfield (Birmingham, United States of America), C. Crim (Research Triangle Park, United States of America), G. Criner (Philadelphia, United States of America), D. Halpin (Exeter, United Kingdom), M. Han (Ann Arbor, United States of America), C. Jones (Research Triangle Park, United States of America), S. Kilbride (Stockley Park West, United Kingdom), P. Lange (Copenhagen, Denmark), D. Lipson (King of Prussia, United States of America), D. Lomas (London, United Kingdom), F. Martinez (New York, United States of America), D. Singh (Manchester, United Kingdom), R. Wise (Baltimore, United States of America)
| |
Eosinophils as a predictor of mepolizumab treatment responses in COPD
I. Pavord (Oxford, United Kingdom), G. Criner (Philadelphia, PA, United States of America), H. Kerstjens (Groningen, Netherlands), E. Bradford (Research Triangle Park, NC, United States of America), S. Schweiker Harris (Research Triangle Park, NC, United States of America), O. Keene (Stockley Park West, Uxbridge, Middlesex, United Kingdom), B. Mayer (Stockley Park West, Uxbridge, Middlesex, United Kingdom), D. Rubin (Stockley Park West. Uxbridge, Middlesex, United Kingdom), S. Yancey (Research Triangle Park, NC, United States of America), D. Bratton (Stockley Park, Uxbridge, Middlesex, United Kingdom)
| |
Reduced glucocorticoid receptor binding affinity in blood lymphocytes and monocytes of COPD patients
A. Tahanovich (Minsk, Belarus), . Kadushkin (Minsk, Belarus), . Movchan (Minsk, Belarus), . Shman (Minsk, Belarus), . Levandovskaya (Minsk, Belarus)
| |
Real-life data on COPD treatment
L. Karimi (Rotterdam, Netherlands), E. Baan (Rotterdam, Netherlands), T. Geeraerd (Ghent, Belgium), J. Van Der Lei (Rotterdam, Netherlands), B. Stricker (Rotterdam, Netherlands), G. Brusselle (Ghent, Belgium), L. Lahousse (Ghent, Belgium), K. Verhamme (Rotterdam, Netherlands)
| |
Personalized treatment through an inhaler device, adjustable to patient's respiratory profile
P. Zarogoulidis (Thessaloniki, Greece), S. Rozou (Thessaloniki, Greece), K. Porpodis (Thessaloniki, Greece), K. Domvri (Thessaloniki, Greece), N. Michailidis (Thessaloniki, Greece), S. Petanidis (Thessaloniki, Greece), E. Kioseoglou (Thessaloniki, Greece), D. Psalla (Thessaloniki, Greece), K. Zarogoulidis (Thessaloniki, Greece)
| |
Single inhaler triple therapy in patients with COPD: patient-reported dyspnoea and health status from the IMPACT Trial
M. Tabberer (Middlesex, United Kingdom), C. Jones (Research Triangle Park, United States of America), S. Kilbride (Middlesex, United Kingdom), G. Criner (Philadelphia, United States of America), P. Lange (Copenhagen, Denmark), M. Han (Ann Arbor, United States of America), F. Martinez (New York, United States of America), D. Lipson (King of Prussia, United States of America)
| |
FACTORS INFLUENCING PHARMACOLOGICAL TREATMENT IN COPD PATIENTS ENROLED IN AN INTEGRATED DISEASE MANAGEMENT PROGRAMME (IDMP)
M. Moretti (Massa, Italy), S. Balestracci (Massa, Italy), M. Latorre (Massa, Italy), A. Porcu (Massa, Italy), A. Rocchi (Massa, Italy)
| |
Can a telemonitoring system lead to decreased hospital admissions in elderly patients?
J. Lyth (Linköping, Sweden), L. Lind (Linköping, Sweden), D. Karlsson (Stockholm, Sweden), L. Persson (Linköping, Sweden), A. WiréHn (Linköping, Sweden)
| |
An evaluation of ‘care bundles’ as a means of improving hospital care for patients with COPD: results of a multi-centre study in the UK
J. Calvert (Bristol, United Kingdom), K. Morton (Bristol, United Kingdom), E. Sanderson (Bristol, United Kingdom), P. Dixon (Bristol, United Kingdom), S. Jenkins (Bristol, United Kingdom), S. Macneill (Bristol, United Kingdom), C. Metcalfe (Bristol, United Kingdom), A. Shaw (Bristol, United Kingdom), M. Chalder (Bristol, United Kingdom), W. Hollingsworth (Bristol, United Kingdom), J. Benger (Bristol, United Kingdom), S. Purdy (Bristol, United Kingdom)
| |
Implementation of an integrated care pathway based in a population health approach in Bilbao for Chronic Obstructive Pulmonary Disease patients
M. Martínez (Bilbao, Spain), I. Arriaga-Lariz (Bilbao, Spain), G. Fernández-Peñalba (Bilbao, Spain)
| |
Cost-effectiveness analysis of a Home-based disease management intervention for patients with severe COPD alongside the COMET study.
J. Bourbeau (Montréal, Canada), R. Kessler (Strasbourg, France), I. Durand-Zaleski (Paris, France), S. Roze (Lyon, France), D. GRANADOS (Gentilly, France)
| |
Clinical management of patients newly diagnosed with COPD through targeted case finding and routine care: a longitudinal analysis of the TargetCOPD trial
S. Haroon (Birmingham, United Kingdom), A. Dickens (Birmingham, United Kingdom), P. Adab (Birmingham, United Kingdom), A. Enocson (Birmingham, United Kingdom), D. Fitzmaurice (Birmingham, United Kingdom), R. Jordan (Birmingham, United Kingdom)
| |
Healthcare resource consumption in Italian patients with COPD: The MISTRAL study
G. Vallo (Como, Italy), G. Catapano (Pisa, Italy), D. R. Bonardi (Casatenovo , Italy), C. Pomari (Negrar Verona , Italy), F. Tursi (Lodi, Italy), . Bartezaghi (Origgio, Italy), P. A. Porpiglia (Origgio, Italy), P. Morini (Origgio, Italy)
| |
Comparison of Clinical Efficacy and Safety between ultraLABAs and ultraLAMAs in Patients with COPD: A Systemic Review with a Meta-Analysis of Randomized Controlled Trials
E. CHO (Seoul, Republic of Korea), S. Kim (Seoul, Republic of Korea), N. Kang (Seoul, Republic of Korea), Y. Im (Seoul, Republic of Korea), M. Kim (Seoul, Republic of Korea), S. Kim (Seoul, Republic of Korea), D. Park (Seoul, Republic of Korea), K. Yoo (Seoul, Republic of Korea), Y. Park (Seoul, Republic of Korea), J. Jung (Seoul, Republic of Korea), H. Lee (Seoul, Republic of Korea), H. Park (Seoul, Republic of Korea), S. Lim (Seoul, Republic of Korea), H. Park (Seoul, Republic of Korea)
| |
Generating patient insights in chronic obstructive pulmonary disease (COPD) with social media listening study
F. Gutzwiller (Basel, Switzerland), J. Gruenberger (Basel, Switzerland), V. Kaur (Hyderabad, India), P. Pathak (Hyderabad, India), A. Mudumby (Hyderabad, India), N. Cook (Basel, Switzerland)
| |